Natus Medical Incorporated (BABY) : Wednesdays money flow points at investors jumping to buy the stock on the weakness of price. $3.22 million worth of transactions were on upticks, whereas, the downticks accounted for $2.18 million worth of transactions. The net money flow was a positive $1.03 million and the uptick to downtick ratio was 1.47. The net money flow into the stock was $0.73 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0.73 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Natus Medical Incorporated (BABY) was trading at $39.76, down $0.55 during day. The stock slid -1.35% over the previous days close. For the week, the stock recorded -2.21% over the previous weeks close.
Also, Roth Capital maintains its rating on Natus Medical Incorporated (NASDAQ:BABY). The global brokerage major lowers the current price target from $44 per share to $39 per share. Analysts at the Roth Capital have a current rating of Buy on the shares. The rating by the firm was issued on April 5, 2016.
Natus Medical Incorporated (NASDAQ:BABY): The stock opened at $40.83 on Wednesday but the bulls could not build on the opening and the stock topped out at $41.28 for the day. The stock traded down to $38.91 during the day, due to lack of any buying support eventually closed down at $39.47 with a loss of -2.06% for the day. The stock had closed at $40.30 on the previous day. The total traded volume was 948,478 shares.
The stock has recorded a 20-day Moving Average of 2.91% and the 50-Day Moving Average is 10.66%. In a related news,The director of Natus Medical Inc, Gunst Robert A sold 5,000 shares at $34.61 on April 26, 2016. The Insider selling transaction had a total value worth of $173,050. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company offers two product families: Neurology, which includes products and services for diagnostic electroencephalography and long term monitoring, intensive care unit monitoring, electromyography, sleep analysis, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care, which includes products and services for newborn care, including hearing screening, brain injury, thermoregulation, jaundice management and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and others.